European Investor
10 Nov 2026, 09:38
Amgen Highlights Repatha Cost-Effectiveness and Long-Term Cardiovascular Risk Reduction at AHA 2026
Amgen (NASDAQ: AMGN) presented new Repatha data at the American Heart Association Scientific Sessions 2026, strengthening the case for earlier and more intensive LDL cholesterol lowering in high-risk cardiovascular patients. :chatgpt-content-reference{index="0"}
An independent analysis of the Phase 3 VESALIUS-CV trial found Repatha to be highly cost-effective in high-risk patients without a prior heart attack or stroke, at approximately 36% below the ACC/AHA benchmark. A separate analysis also found Repatha cost-effective when added to standard therapy in patients with established atherosclerotic cardiovascular disease. :chatgpt-content-reference{index="1"}
Additional VESALIUS-CV data showed particularly strong benefits in patients with chronic kidney disease. Over a median 4.6 years, Repatha reduced the risk of three-point major adverse cardiovascular events by 39%, four-point MACE by 23% and all-cause mortality by 29% in patients with CKD and no prior heart attack or stroke. :chatgpt-content-reference{index="2"}
Amgen also presented a long-term FOURIER external-control analysis showing Repatha was associated with a 29% lower rate of major cardiovascular events and a 25% lower risk of cardiovascular death over more than eight years of follow-up. :chatgpt-content-reference{index="3"}
The new analyses reinforce Amgen’s effort to expand Repatha’s role beyond secondary prevention, supporting earlier treatment in high-risk patients and strengthening the drug’s long-term clinical and economic value proposition.
Amgen (NASDAQ: AMGN) presented new Repatha data at the American Heart Association Scientific Sessions 2026, strengthening the case for earlier and more intensive LDL cholesterol lowering in high-risk cardiovascular patients. :chatgpt-content-reference{index="0"}
An independent analysis of the Phase 3 VESALIUS-CV trial found Repatha to be highly cost-effective in high-risk patients without a prior heart attack or stroke, at approximately 36% below the ACC/AHA benchmark. A separate analysis also found Repatha cost-effective when added to standard therapy in patients with established atherosclerotic cardiovascular disease. :chatgpt-content-reference{index="1"}
Additional VESALIUS-CV data showed particularly strong benefits in patients with chronic kidney disease. Over a median 4.6 years, Repatha reduced the risk of three-point major adverse cardiovascular events by 39%, four-point MACE by 23% and all-cause mortality by 29% in patients with CKD and no prior heart attack or stroke. :chatgpt-content-reference{index="2"}
Amgen also presented a long-term FOURIER external-control analysis showing Repatha was associated with a 29% lower rate of major cardiovascular events and a 25% lower risk of cardiovascular death over more than eight years of follow-up. :chatgpt-content-reference{index="3"}
The new analyses reinforce Amgen’s effort to expand Repatha’s role beyond secondary prevention, supporting earlier treatment in high-risk patients and strengthening the drug’s long-term clinical and economic value proposition.
